Check out our new Impact Fund in the FT. Our new Life Impact Fund has been featured in FT Adviser. Ideal for private investors, the fund’s purpose is to ‘enrich people’s lives’. Target investments are businesses with disruptive technologies that have the potential to positively impact at least 100 million human lives, as well as…

Inotec AMD, a Cambridge based, fast-growing medtech business that has developed a novel device capable of healing complex chronic wounds, has secured investment of £7m. The funding round wasled by Praetura Capital, with involvement from Boundary Capital Partners LLP. The business has developed a world leading medtech product, called NATROX® Oxygen, for use in Wound…

Boundary Capital Partners LLP is authorised and regulated by the Financial Conduct Authority.
Boundary Capital Partners LLP Reg: OC387581 VAT: 204012873
Registered office: 35 Kingsland Road, London, England, E2 8AA

STAY CONNECTED WITH US: